Physician profile
Jared C Cox
NPI 1417204801
$3,974.13
in general payments reported to CMS, 2019-2025
24 companies · $524 in 2025
The $524 reported for 2025 was more than what 78% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,080 · 2020: $479 · 2021: $450 · 2022: $288 · 2023: $663 · 2024: $491 · 2025: $524.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,678.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,678.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $572.61 | 2019-2025 | Cequa |
| Novartis Pharmaceuticals Corporation | $548.69 | 2019-2023 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $420.40 | 2019-2021 | |
| Alcon Vision LLC | $367.62 | 2019-2025 | Tryptyr, Eysuvis, Total30 |
| Aerie Pharmaceuticals, INC. | $278.29 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $248.10 | 2024-2025 | Xdemvy |
| Oyster Point Pharma, INC. | $207.20 | 2022-2024 | Tyrvaya |
| Coopervision INC. | $189.03 | 2019-2025 | Misight Contact Lens, Myday Contact Lens |
| Bausch & Lomb Americas INC. | $185.92 | 2023-2025 | Xiidra, Miebo, Infuse |
| Visioneering Technologies, INC. | $149.10 | 2019 | |
| Allergan, INC. | $145.65 | 2019-2022 | |
| Biotissue Holdings INC. | $120.53 | 2023 | |
| Johnson & Johnson Vision Care, INC. | $94.83 | 2019 | |
| Abbvie INC. | $74.92 | 2024-2025 | |
| Ocular Therapeutix, INC. | $54.60 | 2024-2025 | Dextenza |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kala Pharmaceuticals, INC. | $52.91 | 2021 | |
| Intuitive Surgical, INC. | $50.20 | 2019 | |
| Dompe US, INC. | $45.13 | 2019-2025 | Oxervate |
| Optos, INC. | $38.92 | 2020 | |
| Sight Sciences, INC. | $37.68 | 2019-2020 | |
| Horizon Therapeutics Plc | $31.13 | 2023 | Tepezza |
| Astellas Pharma US INC | $26.84 | 2023 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Spark Therapeutics, INC. | $14.43 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jared Cox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.